Loading...
Market
Crenessity to lead CAH treatment market by market share by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Market research reports and pharmaceutical sales data
Story
FDA Approves Neurocrine Biosciences' Crenessity, First New Treatment for CAH in 70 Years
Dec 13, 2024, 08:13 PM
The U.S. Food and Drug Administration (FDA) has approved Neurocrine Biosciences' Crenessity (crinecerfont) for the treatment of adults and pediatric patients over 4 years of age with classic congenital adrenal hyperplasia (CAH). This approval marks the first new treatment option for CAH in 70 years, offering a paradigm-shifting approach by directly reducing excess adrenocorticotropic hormone (ACTH) and downstream adrenal androgen production, allowing for glucocorticoid dose reduction. The approval was supported by data from the largest-ever clinical trial program in pediatric and adult patients with classic CAH. Crenessity is expected to be commercially available in approximately one week.
View original story
Similar markets
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Ascendis Pharma • 25%
Takeda • 25%
Another existing company • 25%
A new entrant • 25%
DDL-920 • 25%
Aduhelm • 25%
Leqembi • 25%
Other • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
Yes • 50%
No • 50%
Avadel Pharmaceuticals • 25%
Jazz Pharmaceuticals • 25%
Another Company • 25%
No Dominant Player • 25%
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%